# Fusion Biopsy Market > Fusion Biopsy Market Research Report By Tech Target (DNA, RNA, Protein), By Product (Multi-gene Panels, Single-gene Tests, Companion Diagnostics, Research Use Only (RUO) Kits), By Application (Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Digital PCR, NanoString Technologies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.65% - **2024:** $ 0.85 Billion - **2025:** $ 0.92 Billion - **2035:** $ 1.91 Billion - **Key Players:** Exact Sciences (US), Fujifilm (JP), Siemens Healthineers (DE), GE Healthcare (US), Philips (NL), Civco Medical Solutions (US), Medtronic (IE), Bard (US), Boston Scientific (US) **Report ID:** MRFR/HC/25540-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/fusion-biopsy-market-27210 --- ## Market Summary ## **Fusion Biopsy Market Overview** As per MRFR analysis, the Fusion Biopsy Market Size was estimated at 0.77 (USD Billion) in 2023. The Fusion Biopsy Market Industry is expected to grow from 0.85 (USD Billion) in 2024 to 1.64 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 7.65% during the forecast period (2024 - 2032). ### **Key Fusion Biopsy Market Trends Highlighted** Key market drivers for fusion biopsy include advancements in molecular profiling and targeted therapies, the rising prevalence of cancer, and technological advancements. Opportunities lie in the development of novel fusion biopsy techniques, expanding applications in precision oncology, and the growing adoption of liquid biopsies. Recent trends in the global fusion biopsy market include the integration of artificial intelligence and machine learning for improved diagnostic accuracy, the adoption of minimally invasive procedures, and the development of personalized treatment plans based on fusion biopsy results. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Fusion Biopsy Market Drivers** ### **Technological Advancements Driving Precision Medicine** With the introduction of various advanced technologies such as next-generation sequencing, the precision medicine technique has become more efficient, and the growth of the Global Fusion Biopsy Market is expected as the procedure of patient-specific biology becomes quite possible. Such technologies enable the ability to analyze the particular changes of genes related to tumors in a patient. ### **Rising Prevalence of Cancer and Need for Early Detection** The incidence of cancer is on the rise globally, with an estimated 19.3 million new cases diagnosed in 2020. The need for early detection and accurate diagnosis is paramount to improve patient outcomes. Fusion biopsies offer a minimally invasive and highly sensitive method for detecting cancer at an early stage when treatment options are more effective. The increasing prevalence of cancer and the growing demand for early detection are expected to fuel the growth of the Global Fusion Biopsy Market. ### **Growing Adoption of Liquid Biopsies** Liquid biopsies, which analyze cell-free nucleic acids (cfNAs) in peripheral blood, offer a non-invasive alternative to traditional tissue biopsies. Fusion biopsies can be performed using liquid biopsies, enabling the detection of genomic alterations in circulating tumor cells (CTCs) or cfNAs. The growing adoption of liquid biopsies for cancer detection and monitoring is expected to drive demand for fusion biopsies in the Global Fusion Biopsy Market. ## **Fusion Biopsy Market Segment Insights** ### **Fusion Biopsy Market Tech Target Insights** The market growth is attributed to the increasing prevalence of cancer, technological advancements, and rising adoption of minimally invasive procedures. DNA, RNA, and protein are the key targets for fusion biopsies. DNA-based fusion biopsies are commonly used to identify genetic alterations, such as gene mutations, deletions, and amplifications, which can provide valuable information for cancer diagnosis, prognosis, and treatment selection. RNA-based fusion biopsies analyze messenger RNA (mRNA) to detect gene expression profiles, which can help identify cancer-specific biomarkers and monitor treatment response. Protein-based fusion biopsies involve the analysis of specific proteins or protein panels to detect cancer-associated alterations, such as over-expression or mutations, which can aid in cancer diagnosis and targeted therapy selection. The market segmentation provides insights into the specific application areas and target molecules of fusion biopsies. DNA-based fusion biopsies held the largest market share in 2023, and it is projected to maintain its dominance throughout the forecast period. This is primarily due to the extensive use of DNA-based technologies in cancer genomics and the well-established role of DNA alterations in cancer development. RNA-based fusion biopsies are expected to witness significant growth, driven by the increasing adoption of RNA sequencing technologies and the potential of RNA biomarkers for cancer diagnosis and prognosis. Protein-based fusion biopsies are gaining traction due to their ability to detect post-translational modifications and protein-protein interactions, which can provide complementary information to DNA- and RNA-based analyses. Overall, the market for fusion biopsies is poised for substantial growth, driven by the increasing demand for personalized and targeted cancer therapies, technological advancements, and the growing prevalence of cancer worldwide. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Fusion Biopsy Market Product Insights** The product segment of the Global Fusion Biopsy Market is classified into Multi-gene Panels, Single-gene Tests, Companion Diagnostics, and Research Use Only (RUO) Kits. In 2023, the Multi-gene Panels segment held the largest market share at around 42.5%. The growth of this segment can be attributed to the increasing adoption of next-generation sequencing (NGS) technology, which allows for the simultaneous analysis of multiple genes. The Single-gene Tests segment is expected to witness significant growth in the coming years, owing to the rising demand for personalized medicine and the development of targeted therapies. The Companion Diagnostics segment is also expected to grow at a robust pace, driven by the increasing use of companion diagnostics to guide treatment decisions. The Research Use Only (RUO) Kits segment is expected to grow at a moderate pace, as these kits are primarily used in research settings and are not approved for clinical use. ### **Fusion Biopsy Market Application Insights** The Global Fusion Biopsy Market for various applications, including oncology, neurology, infectious diseases, and cardiovascular diseases, presents a diverse landscape with distinct growth trajectories and market dynamics. Oncology holds the largest market share due to the increasing prevalence of cancer and the growing adoption of precision medicine approaches. The Global Fusion Biopsy Market revenue for oncology applications is projected to reach $7.2 billion by 2024, driven by the rising demand for minimally invasive biopsy techniques and the development of targeted therapies. Neurology applications are also witnessing significant growth, owing to the increasing incidence of neurological disorders and the need for accurate diagnosis. Infectious diseases and cardiovascular diseases applications are expected to grow steadily, supported by advancements in molecular diagnostics and the need for early detection and personalized treatment strategies. ### **Fusion Biopsy Market Technology Insights** The Global Fusion Biopsy Market is segmented by technology into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Digital PCR, and NanoString Technologies. NGS is expected to dominate the market with a significant revenue share in 2024, owing to its ability to identify a wide range of genomic alterations with high accuracy. PCR, which is a well-established technology for DNA amplification, is anticipated to account for a considerable market share. Digital PCR, known for its high precision and sensitivity in detecting rare mutations, is projected to witness substantial growth. NanoString Technologies, a versatile platform for gene expression analysis and biomarker detection, is poised to gain traction in the fusion biopsy market. The market growth for these technologies is driven by increasing demand for personalized medicine, advancements in cancer diagnostics, and technological innovations. ### **Fusion Biopsy Market Regional Insights** The Global Fusion Biopsy Market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East and Africa. The market in North America held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. This growth is attributed to the increasing adoption of fusion biopsy in prostate cancer diagnosis and the presence of major market players in the region. Europe is expected to be the second-largest market for fusion biopsy, with a significant market share in 2023. The growing awareness of prostate cancer and the increasing use of fusion biopsy in the diagnosis of the disease are the major factors driving the market growth in this region. The Asia Pacific region is expected to witness the fastest growth rate during the forecast period, owing to the rising incidence of prostate cancer and the increasing adoption of fusion biopsy in the region. South America and the Middle East and Africa contributed a smaller share to the global Fusion Biopsy Market revenue in 2023, but these regions are expected to experience a steady growth rate during the forecast period. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Fusion Biopsy Market Key Players and Competitive Insights** Major players in the Fusion Biopsy Market are continuously striving to bring innovative products and solutions to the market, leading to intense competition. Fusion Biopsy Market development is constantly evolving, with new technologies and approaches emerging regularly. Leading Fusion Biopsy Market players are investing heavily in research and development, with a focus on improving accuracy, reducing invasiveness, and broadening the scope of applications. The competitive landscape is characterized by strategic alliances, mergers, and acquisitions, as well as ongoing collaborations between various stakeholders in the Fusion Biopsy Market ecosystem. NanoString Technologies, a leading player in the Fusion Biopsy Market, is renowned for its innovative nCounter Analysis System. This proprietary technology enables the precise analysis of RNA and DNA molecules, providing valuable insights into gene expression and genetic alterations. NanoString's commitment to innovation has positioned it as a key player in the rapidly evolving field of precision medicine. InVitae Corporation, a prominent competitor in the Fusion Biopsy Market, offers a comprehensive suite of genomic profiling solutions. Their InVitae Comprehensive Genomic Profiling (CGP) assay provides a detailed analysis of DNA mutations, copy number alterations, and other genetic abnormalities. InVitae's focus on precision oncology has made it a trusted partner for cancer researchers and clinicians worldwide. **Key Companies in the Fusion Biopsy Market Include** ## **Fusion Biopsy Market Developments** Advancements in technology and increasing adoption of minimally invasive procedures are driving market growth. Recent news developments include: In January 2023, Veracyte announced the launch of its new Percepta Genomic Classifier for prostate cancer, which combines genomic and clinical data to provide personalized treatment recommendations. In February 2023, Exact Sciences received FDA approval for its Oncotype DX Breast Recurrence Score test, which predicts the risk of breast cancer recurrence and helps guide treatment decisions. In March 2023, Biocept announced a partnership with Illumina to develop and commercialize next-generation sequencing-based liquid biopsy tests for cancer detection and monitoring. These developments indicate continued innovation and growth in the Fusion Biopsy Market as companies strive to improve patient outcomes and reduce healthcare costs. ## **Fusion Biopsy Market Segmentation Insights** ### **Fusion Biopsy Market Tech Target Outlook** ### **Fusion Biopsy Market Product Outlook** ### **Fusion Biopsy Market Application Outlook** ### **Fusion Biopsy Market Technology Outlook** ### **Fusion Biopsy Market Regional Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure across various regions is a significant factor influencing the Fusion Biopsy Market. As governments and private sectors allocate more funds towards healthcare, there is a corresponding rise in the adoption of advanced medical technologies. This trend is particularly evident in countries investing in cancer care and diagnostic services. Enhanced funding allows healthcare facilities to acquire state-of-the-art equipment and training for medical professionals, facilitating the implementation of fusion biopsy procedures. Consequently, the Fusion Biopsy Market is likely to benefit from this upward trend in healthcare spending, as more institutions seek to provide high-quality diagnostic services. ### Regulatory Support and Guidelines Regulatory support and the establishment of guidelines for prostate cancer diagnosis are crucial drivers for the Fusion Biopsy Market. Regulatory bodies are increasingly recognizing the importance of advanced diagnostic techniques, leading to the development of supportive frameworks that encourage the adoption of fusion biopsy. These guidelines help standardize procedures and ensure patient safety, fostering confidence among healthcare providers. As regulations evolve to accommodate new technologies, the market for fusion biopsy is expected to grow. The proactive stance of regulatory agencies in promoting innovative diagnostic methods is likely to enhance the credibility and acceptance of the Fusion Biopsy Market. ### Increasing Awareness and Education The growing awareness and education surrounding prostate cancer screening and diagnosis are vital drivers for the Fusion Biopsy Market. As patients become more informed about the importance of early detection, the demand for advanced diagnostic methods, including fusion biopsy, is likely to increase. Educational campaigns by healthcare organizations and advocacy groups play a significant role in promoting awareness. This heightened understanding encourages patients to seek out innovative diagnostic options, thereby driving market growth. Furthermore, as more healthcare professionals become trained in fusion biopsy techniques, the adoption rate is expected to rise, contributing to the overall expansion of the Fusion Biopsy Market. ### Growing Prevalence of Prostate Cancer The rising incidence of prostate cancer is a critical driver for the Fusion Biopsy Market. Prostate cancer remains one of the most common cancers among men, with millions diagnosed annually. This increasing prevalence necessitates advanced diagnostic techniques, such as fusion biopsy, which combines MRI and ultrasound imaging to enhance accuracy. As healthcare providers seek to improve patient outcomes, the demand for fusion biopsy procedures is likely to rise. According to recent statistics, prostate cancer accounts for a significant percentage of cancer cases, further emphasizing the need for effective diagnostic tools. The Fusion Biopsy Market is thus positioned to expand as more healthcare facilities adopt these innovative technologies to address the growing patient population. ### Technological Innovations in Biopsy Techniques Technological advancements in biopsy techniques are propelling the Fusion Biopsy Market forward. Innovations such as real-time imaging and automated systems enhance the precision and efficiency of biopsy procedures. These advancements not only improve diagnostic accuracy but also reduce patient discomfort and recovery time. The integration of artificial intelligence in imaging analysis is also gaining traction, allowing for better identification of suspicious lesions. As healthcare providers increasingly adopt these cutting-edge technologies, the market for fusion biopsy is expected to experience substantial growth. The ongoing development of new imaging modalities and tools is likely to further stimulate the Fusion Biopsy Market, making it a focal point for investment and research. ## Future Outlook The Fusion Biopsy Market is projected to grow at a 7.65% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for minimally invasive procedures. **New opportunities:** - Development of AI-driven imaging software for enhanced accuracy in biopsies. Expansion of telemedicine platforms for remote biopsy consultations. Partnerships with healthcare providers for integrated biopsy services. By 2035, the Fusion Biopsy Market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Tech Target: DNA (Largest) vs. RNA (Fastest-Growing) The Fusion Biopsy Market is segmented into three primary technology targets: DNA, RNA, and Protein. Among these, the DNA technology segment dominates the market, significantly contributing to the overall share. RNA technology is emerging rapidly, gaining traction due to its importance in precision medicine and targeted therapies. The increasing awareness of genetic testing has led to broader adoption of DNA-based solutions, while innovative RNA-based techniques offer additional advantages in biomarker discovery and disease diagnostics. Technology: DNA (Dominant) vs. RNA (Emerging) The DNA segment is characterized by its strong presence in the Fusion Biopsy Market, primarily due to its established applications in genetic testing and oncology. This dominance is driven by the growing prevalence of cancer, where DNA sequencing plays a critical role in diagnosis and treatment planning. In contrast, the RNA segment is seen as the emerging player, thanks to advancements in RNA sequencing technologies which facilitate the identification of novel biomarkers. This segment is gaining momentum as researchers focus on understanding gene expression and the role of RNA in disease processes, making it a crucial area of development in the field. ### By Product: Multi-gene Panels (Largest) vs. Companion Diagnostics (Fastest-Growing) In the Fusion Biopsy Market, the product segment is characterized by diverse offerings such as Multi-gene Panels, Single-gene Tests, Companion Diagnostics, and Research Use Only (RUO) Kits. Among these, Multi-gene Panels have emerged as the largest segment, owing to their extensive application in oncology and genetic testing. This segment's ability to analyze multiple genes simultaneously offers a comprehensive approach to precision medicine, making it a preferred choice among healthcare providers. Conversely, Companion Diagnostics is witnessing rapid growth, driven by the increasing demand for personalized medicine and advancements in targeted therapy. This growth trend signals a shifting focus toward integrating diagnostic tests with therapeutic strategies. Multi-gene Panels (Dominant) vs. Companion Diagnostics (Emerging) Multi-gene Panels are currently positioned as the dominant force in the Fusion Biopsy Market due to their broad scope and ability to provide a comprehensive understanding of multiple genetic alterations in tumors. They facilitate informed decision-making in oncology by enabling tailored treatment approaches based on the patient's unique genetic profile. On the other hand, Companion Diagnostics represent an emerging segment, closely linked to the development of personalized therapies. These diagnostics are essential for identifying suitable candidates for specific treatments, thus enhancing treatment efficacy and patient outcomes. The synergy between these two segments underscores a pivotal shift towards personalized healthcare, where diagnostic testing plays a crucial role in optimizing therapeutic interventions. ### By Application: Oncology (Largest) vs. Neurology (Fastest-Growing) In the Fusion Biopsy Market, the Application segment demonstrates varied market share distribution, with oncology being the largest contributor due to its significant prevalence rates and the critical need for effective diagnostic tools. Following closely, neurology is emerging as a vital application area influenced by growing awareness around neurological disorders, paving the way for innovative biopsy techniques tailored to brain conditions. Oncology (Dominant) vs. Neurology (Emerging) Oncology remains the dominant application in the Fusion Biopsy Market, driven by increasing cancer incidence and advancements in minimally invasive procedures. It focuses on precision targeting of tumors, ensuring higher effectiveness in diagnosis and treatment planning. In contrast, neurology represents an emerging application, flourishing due to increased research activities and the advent of novel imaging technologies that have enhanced the accuracy of biopsies for neurological diseases, positioning itself as a key area for future innovations. ### By Technology: Next-Generation Sequencing (NGS) (Largest) vs. Polymerase Chain Reaction (PCR) (Fastest-Growing) Within the Fusion Biopsy Market, Next-Generation Sequencing (NGS) holds the largest market share owing to its increasing adoption in precision medicine and extensive applications in oncology. Polymerase Chain Reaction (PCR) follows as a vital technology, showing robust growth due to its efficiency and accuracy in genetic analysis and diagnostics. Both technologies play essential roles, with NGS dominating due to its high throughput and comprehensive data generation, while PCR is essential for many laboratories due to its reliability and speed. The Fusion Biopsy Market is witnessing dynamic growth trends primarily driven by advancements in genomic technologies and rising demand for personalized medicine. NGS is leading the charge, providing detailed insights into genetic variations, significantly impacting cancer research and treatment. Conversely, PCR technology is gaining traction for its rapid testing capabilities and adaptability, especially in emerging markets. Overall, the segment is set for continued expansion as technological innovations and clinical needs evolve, paving the way for enhanced diagnostic accuracy and treatment options. Technology: NGS (Dominant) vs. Digital PCR (Emerging) Next-Generation Sequencing (NGS) is currently the dominant technology within the Fusion Biopsy Market, characterized by its ability to process vast amounts of genetic information quickly and accurately. This technology is essential for identifying genetic mutations and chromosomal abnormalities, thus playing a crucial role in personalized medicine and targeted therapies. On the other hand, Digital PCR is an emerging technology, recognized for its sensitivity and precision in quantifying nucleic acids. It provides a reliable method for detecting low-frequency mutations, enhancing the capabilities of traditional PCR techniques. While NGS drives extensive comprehensive sequencing efforts, Digital PCR fills the gap for precise quantification and is poised to complement existing methods, making it an integral part of the evolving fusion biopsy landscape. ## Regional Market Share Analysis ### North America : Leading Innovation and Demand North America is the largest market for fusion biopsy, holding approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of cancer, and rising demand for minimally invasive procedures. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of innovative technologies and treatments. The United States is the primary contributor, with significant investments in research and development. Key players such as Exact Sciences and GE Healthcare are at the forefront, enhancing competition and innovation. The presence of established healthcare systems and a focus on patient-centric solutions bolster the Fusion Biopsy Market, making it a hub for technological advancements in fusion biopsy. ### Europe : Emerging Regulatory Frameworks Europe is the second-largest market for fusion biopsy, accounting for around 30% of the global share. The region benefits from stringent regulatory frameworks that promote safety and efficacy in medical devices. Increasing awareness of early cancer detection and advancements in imaging technologies are key growth drivers. Countries like Germany and the UK are leading the charge, supported by favorable healthcare policies and funding for innovative medical solutions. Germany stands out as a leader in the Fusion Biopsy Market, with a robust healthcare system and significant investments in medical technology. The competitive landscape features major players like Siemens Healthineers and Philips, who are continuously innovating to meet the rising demand. The European market is characterized by collaborations between healthcare providers and technology firms, enhancing the overall service delivery in fusion biopsy. ### Asia-Pacific : Rapid Growth and Adoption Asia-Pacific is witnessing rapid growth in the fusion biopsy market, holding approximately 20% of the global share. The region's expansion is fueled by increasing healthcare expenditure, rising cancer incidence, and a growing preference for minimally invasive procedures. Countries like China and Japan are at the forefront, supported by government initiatives aimed at improving healthcare access and technology adoption. China is emerging as a significant player, with substantial investments in healthcare infrastructure and technology. The competitive landscape includes key players like Fujifilm and Medtronic, who are focusing on innovative solutions tailored to local needs. The region's diverse population and varying healthcare systems present both challenges and opportunities for market players, driving the need for customized approaches in fusion biopsy. ### Middle East and Africa : Untapped Potential and Growth The Middle East and Africa region is gradually emerging in the fusion biopsy market, currently holding about 5% of the global share. The growth is driven by increasing awareness of cancer screening and the need for advanced diagnostic tools. Government initiatives aimed at improving healthcare infrastructure and access to medical technologies are pivotal in this region. Countries like South Africa and the UAE are leading the way, with investments in healthcare modernization. The competitive landscape is still developing, with local and international players vying for market share. Key players are beginning to establish a presence, focusing on education and training to enhance the adoption of fusion biopsy technologies. The region's unique challenges, such as varying healthcare standards, present opportunities for innovative solutions tailored to local needs. ## Competitive Benchmarking The Fusion Biopsy Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for precise diagnostic solutions. Key players such as Exact Sciences (US), Siemens Healthineers (DE), and GE Healthcare (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Exact Sciences (US) focuses on innovation in molecular diagnostics, aiming to improve patient outcomes through advanced biopsy techniques. Siemens Healthineers (DE) emphasizes digital transformation, integrating AI and machine learning into their imaging systems to enhance diagnostic accuracy. Meanwhile, GE Healthcare (US) is pursuing regional expansion, particularly in emerging markets, to capitalize on the growing need for advanced healthcare solutions. The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market presence. Localizing manufacturing and optimizing supply chains are prevalent strategies, allowing companies to respond swiftly to market demands. The Fusion Biopsy Market appears moderately fragmented, with a mix of established players and emerging entrants, each contributing to a competitive structure that fosters innovation and collaboration. In August 2025, Exact Sciences (US) announced a strategic partnership with a leading technology firm to develop a next-generation fusion biopsy platform. This collaboration is poised to leverage cutting-edge AI algorithms, potentially revolutionizing the accuracy and efficiency of biopsy procedures. Such a move underscores Exact Sciences' commitment to maintaining its competitive edge through technological innovation. In September 2025, Siemens Healthineers (DE) unveiled a new imaging system that integrates advanced analytics for real-time biopsy guidance. This launch not only enhances the precision of biopsies but also aligns with the company's broader strategy of digitalization in healthcare. By investing in such technologies, Siemens Healthineers is likely to strengthen its market position and attract a broader customer base. In July 2025, GE Healthcare (US) expanded its operations in Asia by establishing a new manufacturing facility dedicated to fusion biopsy technologies. This strategic move is indicative of GE's focus on regional growth and its intent to meet the increasing demand for advanced diagnostic solutions in the Asia-Pacific region. Such expansions may enhance supply chain reliability and reduce lead times for customers. As of October 2025, the Fusion Biopsy Market is witnessing trends that emphasize digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, it is anticipated that competitive differentiation will increasingly hinge on technological advancements and supply chain efficiency, rather than solely on price. This shift suggests a future where innovation and reliability become paramount in the quest for market leadership. ## Recent News & Developments Advancements in technology and increasing adoption of minimally invasive procedures are driving market growth. Recent news developments include: In January 2023, Veracyte announced the launch of its new Percepta Genomic Classifier for prostate cancer, which combines genomic and clinical data to provide personalized treatment recommendations. In February 2023, Exact Sciences received FDA approval for its Oncotype DX Breast Recurrence Score test, which predicts the risk of breast cancer recurrence and helps guide treatment decisions. In March 2023, Biocept announced a partnership with Illumina to develop and commercialize next-generation sequencing-based [liquid biopsy](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) tests for cancer detection and monitoring. These developments indicate continued innovation and growth in the Fusion Biopsy Market as companies strive to improve patient outcomes and reduce healthcare costs. ## Report Scope | MARKET SIZE 2024 | 0.85(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 0.915(USD Billion) | | MARKET SIZE 2035 | 1.913(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.65% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Exact Sciences (US), Fujifilm (JP), Siemens Healthineers (DE), GE Healthcare (US), Philips (NL), Civco Medical Solutions (US), Medtronic (IE), Bard (US), Boston Scientific (US) | | Segments Covered | Tech Target, Product, Application, Technology, Regional | | Key Market Opportunities | Integration of advanced imaging technologies enhances precision in the Fusion Biopsy Market. | | Key Market Dynamics | Technological advancements and regulatory changes drive growth in the Fusion Biopsy Market, enhancing diagnostic accuracy and efficiency. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Fusion Biopsy Market by 2035?** A: The Fusion Biopsy Market is projected to reach approximately 1.913 USD Billion by 2035. **Q: What was the market valuation of the Fusion Biopsy Market in 2024?** A: In 2024, the Fusion Biopsy Market was valued at around 0.85 USD Billion. **Q: What is the expected CAGR for the Fusion Biopsy Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Fusion Biopsy Market during the forecast period 2025 - 2035 is 7.65%. **Q: Which companies are considered key players in the Fusion Biopsy Market?** A: Key players in the Fusion Biopsy Market include Exact Sciences, Fujifilm, Siemens Healthineers, GE Healthcare, and Philips. **Q: What are the main segments of the Fusion Biopsy Market?** A: The main segments of the Fusion Biopsy Market include Technology, Product, and Application. **Q: How did the DNA segment perform in the Fusion Biopsy Market in 2024?** A: In 2024, the DNA segment was valued between 0.25 and 0.55 USD Billion. **Q: What is the valuation range for Oncology applications in the Fusion Biopsy Market?** A: The valuation range for Oncology applications in the Fusion Biopsy Market is between 0.425 and 0.975 USD Billion. **Q: What technologies are driving growth in the Fusion Biopsy Market?** A: Technologies such as Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) are driving growth in the Fusion Biopsy Market. **Q: What is the projected valuation for Multi-gene Panels in the Fusion Biopsy Market by 2035?** A: The projected valuation for Multi-gene Panels in the Fusion Biopsy Market is expected to be between 0.25 and 0.55 USD Billion. **Q: How does the Fusion Biopsy Market's growth compare across different applications?** A: The Fusion Biopsy Market shows varying growth across applications, with Oncology leading, followed by Neurology and Infectious Diseases. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/fusion-biopsy-market-27210*